Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in Oncol Rep

Retrieve available abstracts of 89 articles:
HTML format
Text format



Single Articles


    February 2019
  1. GUTTLER A, Theuerkorn K, Riemann A, Wichmann H, et al
    Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells.
    Oncol Rep. 2019 Feb 5. doi: 10.3892/or.2019.7001.
    PubMed     Text format     Abstract available


  2. MA Z, Liu X, Zhang Q, Yu Z, et al
    Carvedilol suppresses malignant proliferation of mammary epithelial cells through inhibition of the ROSmediated PI3K/AKT signaling pathway.
    Oncol Rep. 2019;41:811-818.
    PubMed     Text format     Abstract available


    January 2019
  3. FONTES-SOUSA M, Amorim M, Salta S, Palma De Sousa S, et al
    Predicting resistance to endocrine therapy in breast cancer: It's time for epigenetic biomarkers (Review).
    Oncol Rep. 2019 Jan 11. doi: 10.3892/or.2019.6967.
    PubMed     Text format     Abstract available


  4. WEI CW, Yu YL, Chen YH, Hung YT, et al
    Anticancer effects of methotrexate in combination with alphatocopherol and alphatocopherol succinate on triplenegative breast cancer.
    Oncol Rep. 2019 Jan 9. doi: 10.3892/or.2019.6958.
    PubMed     Text format     Abstract available


  5. SCHRODER L, Marahrens P, Koch JG, Heidegger H, et al
    Effects of green tea, matcha tea and their components epigallocatechin gallate and quercetin on MCF7 and MDA-MB-231 breast carcinoma cells.
    Oncol Rep. 2019;41:387-396.
    PubMed     Text format     Abstract available


    December 2018
  6. MA J, Niu W, Wang X, Zhou Y, et al
    Bromodomaincontaining protein 7 sensitizes breast cancer cells to paclitaxel by activating Bcl2antagonist/killer protein.
    Oncol Rep. 2018 Dec 21. doi: 10.3892/or.2018.6951.
    PubMed     Text format     Abstract available


  7. KIM S, You D, Jeong Y, Yu J, et al
    TP53 upregulates alphasmooth muscle actin expression in tamoxifenresistant breast cancer cells.
    Oncol Rep. 2018 Dec 6. doi: 10.3892/or.2018.6910.
    PubMed     Text format     Abstract available


  8. HUANG S, Yuan N, Wang G, Wu F, et al
    Cellular communication promotes mammosphere growth and collective invasion through microtubulelike structures and angiogenesis.
    Oncol Rep. 2018;40:3297-3312.
    PubMed     Text format     Abstract available


    November 2018
  9. JING X, Liang H, Hao C, Yang X, et al
    Overexpression of MUC1 predicts poor prognosis in patients with breast cancer.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6887.
    PubMed     Text format     Abstract available


  10. YAO R, Wang Y, Han D, Ma Y, et al
    Lysines 207 and 325 methylation of WDR5 catalyzed by SETD6 promotes breast cancer cell proliferation and migration.
    Oncol Rep. 2018;40:3069-3077.
    PubMed     Text format     Abstract available


  11. HUANG XJ, Xia Y, He GF, Zheng LL, et al
    MALAT1 promotes angiogenesis of breast cancer.
    Oncol Rep. 2018;40:2683-2689.
    PubMed     Text format     Abstract available


  12. HENG ZSL, Lee JY, Subhramanyam CS, Wang C, et al
    The role of 17betaestradiolinduced upregulation of Piwilike 4 in modulating gene expression and motility in breast cancer cells.
    Oncol Rep. 2018;40:2525-2535.
    PubMed     Text format     Abstract available


  13. YANG PJ, Hou MF, Tsai EM, Liang SS, et al
    Breast cancer is associated with methylation and expression of the a disintegrin and metalloproteinase domain 33 (ADAM33) gene affected by endocrinedisrupting chemicals.
    Oncol Rep. 2018;40:2766-2777.
    PubMed     Text format     Abstract available


  14. ZHU L, Li XX, Shi L, Wu J, et al
    Rapamycin enhances the sensitivity of ERpositive breast cancer cells to tamoxifen by upregulating p73 expression.
    Oncol Rep. 2018 Nov 1. doi: 10.3892/or.2018.6842.
    PubMed     Text format     Abstract available


  15. KIM MH, Park JW, Lee EJ, Kim S, et al
    C16ceramide and sphingosine 1phosphate/S1PR2 have opposite effects on cell growth through mTOR signaling pathway regulation.
    Oncol Rep. 2018;40:2977-2987.
    PubMed     Text format     Abstract available


    October 2018
  16. XIE WY, He RH, Zhang J, He YJ, et al
    betablockers inhibit the viability of breast cancer cells by regulating the ERK/COX2 signaling pathway and the drug response is affected by ADRB2 singlenucleotide polymorphisms.
    Oncol Rep. 2018 Oct 29. doi: 10.3892/or.2018.6830.
    PubMed     Text format     Abstract available


  17. EL-TABBA' RM, Mathew P, Masocha W, Khajah MA, et al
    COL3 enhances the antiproliferative and proapoptotic effects of paclitaxel in breast cancer cells.
    Oncol Rep. 2018 Oct 22. doi: 10.3892/or.2018.6815.
    PubMed     Text format     Abstract available


  18. LI W, Yang H, Li X, Han L, et al
    Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer.
    Oncol Rep. 2018 Oct 18. doi: 10.3892/or.2018.6805.
    PubMed     Text format     Abstract available


  19. WANG L, Shi H, Zhang X, Zhang X, et al
    I157172, a novel inhibitor of cystathionine gamma-lyase, inhibits growth and migration of breast cancer cells via SIRT1-mediated deacetylation of STAT3.
    Oncol Rep. 2018 Oct 16. doi: 10.3892/or.2018.6798.
    PubMed     Text format     Abstract available


  20. ZHAO Y, Onda K, Sugiyama K, Yuan B, et al
    Antitumor effects of arsenic disulfide on the viability, migratory ability, apoptosis and autophagy of breast cancer cells.
    Oncol Rep. 2018 Oct 9. doi: 10.3892/or.2018.6780.
    PubMed     Text format     Abstract available


  21. SHETTAR A, Damineni S, Mukherjee G, Kondaiah P, et al
    Gap junction beta2 expression is negatively associated with the estrogen receptor status in breast cancer tissues and is a regulator of breast tumorigenesis.
    Oncol Rep. 2018 Oct 3. doi: 10.3892/or.2018.6764.
    PubMed     Text format     Abstract available


  22. ZHU L, Zhou W, Zhu X, Xiang S, et al
    Inhibitor of apoptosis proteinlike protein2: A novel growth accelerator for breast cancer cells.
    Oncol Rep. 2018;40:2047-2055.
    PubMed     Text format     Abstract available


  23. JIN ZQ, Hao J, Yang X, He JH, et al
    Higenamine enhances the antitumor effects of cucurbitacin B in breast cancer by inhibiting the interaction of AKT and CDK2.
    Oncol Rep. 2018;40:2127-2136.
    PubMed     Text format     Abstract available


  24. ZHUO Y, Li X, Zheng Q, Fan X, et al
    Estrogen enhances tumor growth and angiogenesis indirectly via mediation of bone marrowderived cells as well as directly through stimulation of tumor and endothelial cells.
    Oncol Rep. 2018;40:2147-2156.
    PubMed     Text format     Abstract available


  25. NETSIRISAWAN P, Chaiyawat P, Chokchaichamnankit D, Lirdprapamongkol K, et al
    Decreasing O-GlcNAcylation affects the malignant transformation of MCF-7 cells via Hsp27 expression and its O-GlcNAc modification.
    Oncol Rep. 2018;40:2193-2205.
    PubMed     Text format     Abstract available


  26. ALSAMMAN K, El-Masry OS
    Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62.
    Oncol Rep. 2018;40:2157-2162.
    PubMed     Text format     Abstract available


  27. SUN X, Zhang H, Zhang Y, Yang Q, et al
    Caspase-dependent mitochondrial apoptotic pathway is involved in astilbin-mediated cytotoxicity in breast carcinoma cells.
    Oncol Rep. 2018;40:2278-2286.
    PubMed     Text format     Abstract available


  28. LIAO S, Gan L, Qin W, Liu C, et al
    Inhibition of GSK3 and MEK induced cancer stem cell generation via the Wnt and MEK signaling pathways.
    Oncol Rep. 2018;40:2005-2013.
    PubMed     Text format     Abstract available


    September 2018
  29. XIE D, Song H, Wu T, Li D, et al
    MicroRNA424 serves an antioncogenic role by targeting cyclindependent kinase 1 in breast cancer cells.
    Oncol Rep. 2018 Sep 27. doi: 10.3892/or.2018.6741.
    PubMed     Text format     Abstract available


  30. CHEN J, Tian W, He H, Chen F, et al
    Downregulation of miR200c3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2.
    Oncol Rep. 2018 Sep 26. doi: 10.3892/or.2018.6735.
    PubMed     Text format     Abstract available


  31. WANG YJ, Zheng LY, Wang ZF, Song R, et al
    Associations of genewide SNPs in SNAI1 and TWIST1 with breast cancer and ovarian cancer susceptibility among Chinese Han women.
    Oncol Rep. 2018 Sep 21. doi: 10.3892/or.2018.6725.
    PubMed     Text format     Abstract available


  32. ZHAO H, Yang Q, Hu Y, Zhang J, et al
    Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triplenegative breast cancer cells.
    Oncol Rep. 2018 Sep 20. doi: 10.3892/or.2018.6716.
    PubMed     Text format     Abstract available


  33. KO YS, Jin H, Lee JS, Park SW, et al
    Radioresistant breast cancer cells exhibit increased resistance to chemotherapy and enhanced invasive properties due to cancer stem cells.
    Oncol Rep. 2018 Sep 18. doi: 10.3892/or.2018.6714.
    PubMed     Text format     Abstract available


    August 2018
  34. CHEN Y, Wei L, Zhang X, Liu X, et al
    3Bromopyruvate sensitizes human breast cancer cells to TRAILinduced apoptosis via the phosphorylated AMPKmediated upregulation of DR5.
    Oncol Rep. 2018 Aug 14. doi: 10.3892/or.2018.6644.
    PubMed     Text format     Abstract available


  35. GUAN J, Zhou Y, Mao F, Lin Y, et al
    MicroRNA320a suppresses tumor cell growth and invasion of human breast cancer by targeting insulinlike growth factor 1 receptor.
    Oncol Rep. 2018;40:849-858.
    PubMed     Text format     Abstract available


  36. YU Z, Lou L, Zhao Y
    Fibroblast growth factor 18 promotes the growth, migration and invasion of MDAMB231 cells.
    Oncol Rep. 2018;40:704-714.
    PubMed     Text format     Abstract available


    July 2018
  37. TAKEMORI T, Kawamoto T, Ueha T, Toda M, et al
    Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis.
    Oncol Rep. 2018 Jul 30. doi: 10.3892/or.2018.6608.
    PubMed     Text format     Abstract available


  38. CALAF GM, Ponce-Cusi R, Carrion F
    Curcumin and paclitaxel induce cell death in breast cancer cell lines.
    Oncol Rep. 2018 Jul 26. doi: 10.3892/or.2018.6603.
    PubMed     Text format     Abstract available


  39. ZHOU XL, Zeng, Ye YH, Sun SM, et al
    Prognostic values of the inhibitor of DNAbinding family members in breast cancer.
    Oncol Rep. 2018 Jul 23. doi: 10.3892/or.2018.6589.
    PubMed     Text format     Abstract available


  40. WANG H, He Z, Xia L, Zhang W, et al
    PSMB4 overexpression enhances the cell growth and viability of breast cancer cells leading to a poor prognosis.
    Oncol Rep. 2018 Jul 20. doi: 10.3892/or.2018.6588.
    PubMed     Text format     Abstract available


  41. LI S, Dai H, He Y, Peng S, et al
    BMP9 inhibits the growth of breast cancer cells by downregulation of the PI3K/Akt signaling pathway.
    Oncol Rep. 2018 Jul 13. doi: 10.3892/or.2018.6572.
    PubMed     Text format     Abstract available


  42. JI Y, Jiang Q, Jian G, Sun H, et al
    Developing a radiosensitivity gene signature for Caucasian patients with breast cancer.
    Oncol Rep. 2018 Jul 12. doi: 10.3892/or.2018.6567.
    PubMed     Text format     Abstract available


    June 2018
  43. CANZONERI R, Rabassa ME, Gurruchaga A, Ferretti V, et al
    Alternative splicing variant of RHBDD2 is associated with cell stress response and breast cancer progression.
    Oncol Rep. 2018 Jun 14. doi: 10.3892/or.2018.6489.
    PubMed     Text format     Abstract available


  44. ZHAO W, Kuai X, Zhou X, Jia L, et al
    Trop2 is a potential biomarker for the promotion of EMT in human breast cancer.
    Oncol Rep. 2018 Jun 14. doi: 10.3892/or.2018.6496.
    PubMed     Text format     Abstract available


  45. VAKLAVAS C, Zinn KR, Samuel SL, Meng Z, et al
    Translational control of the undifferentiated phenotype in ERpositive breast tumor cells: Cytoplasmic localization of ERalpha and impact of IRES inhibition.
    Oncol Rep. 2018;39:2482-2498.
    PubMed     Text format     Abstract available


  46. ZHANG GM, Goyal H, Song LL
    Bioinformatics analysis of differentially expressed miRNA-related mRNAs and their prognostic value in breast carcinoma.
    Oncol Rep. 2018;39:2865-2872.
    PubMed     Text format     Abstract available


    May 2018
  47. CHOI JW, Moon BI, Lee JW, Kim HJ, et al
    Use of CA153 for screening breast cancer: An antibodylectin sandwich assay for detecting glycosylation of CA153 in sera.
    Oncol Rep. 2018 May 10. doi: 10.3892/or.2018.6433.
    PubMed     Text format     Abstract available


  48. WANG Y, Guo L, Feng L, Zhang W, et al
    Single nucleotide variant profiles of viable single circulating tumour cells reveal CTC behaviours in breast cancer.
    Oncol Rep. 2018;39:2147-2159.
    PubMed     Text format     Abstract available


  49. XU L, Che X, Wu Y, Song N, et al
    SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
    Oncol Rep. 2018;39:2315-2323.
    PubMed     Text format     Abstract available


  50. NUVOLI S, Galassi S, Gelo I, Rocchitta G, et al
    The role of molecular breast imaging in predicting complete tumor response to treatment and residual tumor extent following neoadjuvant therapy.
    Oncol Rep. 2018;39:2055-2062.
    PubMed     Text format     Abstract available


    April 2018
  51. WANG Y, Zhang Z, Wang J
    MicroRNA-384 inhibits the progression of breast cancer by targeting ACVR1.
    Oncol Rep. 2018 Apr 20. doi: 10.3892/or.2018.6385.
    PubMed     Text format     Abstract available


  52. CALAF GM, Ponce-Cusi R, Abarca-Quinones J
    Effect of curcumin on the cell surface markers CD44 and CD24 in breast cancer.
    Oncol Rep. 2018 Apr 20. doi: 10.3892/or.2018.6386.
    PubMed     Text format     Abstract available


  53. WANG X, Qiu H, Tang R, Song H, et al
    miR30a inhibits epithelialmesenchymal transition and metastasis in triplenegative breast cancer by targeting ROR1.
    Oncol Rep. 2018 Apr 18. doi: 10.3892/or.2018.6379.
    PubMed     Text format     Abstract available


  54. TOPCUL M, Ceti N IL, Ozbas Turan S, Kolusayin Ozar MO, et al
    In vitro cytotoxic effect of PARP inhibitor alone and in combination with nabpaclitaxel on triplenegative and luminal A breast cancer cells.
    Oncol Rep. 2018 Apr 12. doi: 10.3892/or.2018.6364.
    PubMed     Text format     Abstract available


  55. LUO T, Yan Y, He Q, Ma X, et al
    miR-328-5p inhibits MDA-MB-231 breast cancer cell proliferation by targeting RAGE.
    Oncol Rep. 2018 Apr 4. doi: 10.3892/or.2018.6353.
    PubMed     Text format     Abstract available


  56. SHEN Y, Zhong J, Liu J, Liu K, et al
    Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-alpha36.
    Oncol Rep. 2018 Apr 2. doi: 10.3892/or.2018.6350.
    PubMed     Text format     Abstract available


  57. OH YJ, Park SY, Seo YH
    The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
    Oncol Rep. 2018;39:1775-1782.
    PubMed     Text format     Abstract available


    March 2018
  58. LEON-GALICIA I, Diaz-Chavez J, Albino-Sanchez ME, Garcia-Villa E, et al
    Resveratrol decreases Rad51 expression and sensitizes cisplatinresistant MCF7 breast cancer cells.
    Oncol Rep. 2018 Mar 27. doi: 10.3892/or.2018.6336.
    PubMed     Text format     Abstract available


  59. LIN CC, Lo MC, Moody RR, Stevers NO, et al
    Doxycycline targets aldehyde dehydrogenasepositive breast cancer stem cells.
    Oncol Rep. 2018 Mar 27. doi: 10.3892/or.2018.6337.
    PubMed     Text format     Abstract available


  60. LIU M, Liu H, Chen J
    Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review).
    Oncol Rep. 2018;39:901-911.
    PubMed     Text format     Abstract available


    February 2018
  61. RATHINAVELU A, Kanagasabai T, Dhandayuthapani S, Alhazzani K, et al
    Anti-angiogenic and pro-apoptotic effects of a small-molecule JFD-WS in in vitro and breast cancer xenograft mouse models.
    Oncol Rep. 2018 Feb 9. doi: 10.3892/or.2018.6256.
    PubMed     Text format     Abstract available


  62. SHENG C, Qiu J, He Z, Wang H, et al
    Suppression of Kpnbeta1 expression inhibits human breast cancer cell proliferation by abrogating nuclear transport of Her2.
    Oncol Rep. 2018;39:554-564.
    PubMed     Text format     Abstract available


    January 2018
  63. HU B, Meng X, Zhang Y, Hossain MM, et al
    Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF7 cells in vitro and in vivo and its mechanism of action.
    Oncol Rep. 2018 Jan 26. doi: 10.3892/or.2018.6237.
    PubMed     Text format     Abstract available


  64. YIN G, Zeng B, Peng Z, Liu Y, et al
    Synthesis and application of 131I-fulvestrant as a targeted radiation drug for endocrine therapy in human breast cancer.
    Oncol Rep. 2018 Jan 11. doi: 10.3892/or.2018.6212.
    PubMed     Text format     Abstract available


  65. WANG YW, Zhang W, Ma R
    Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data.
    Oncol Rep. 2018 Jan 10. doi: 10.3892/or.2018.6205.
    PubMed     Text format     Abstract available


  66. ZHAO M, Wang Y, Du C, Liu Y, et al
    Aspirin and metformin exhibit antitumor activity in murine breast cancer.
    Oncol Rep. 2018 Jan 4. doi: 10.3892/or.2018.6190.
    PubMed     Text format     Abstract available


  67. KASORN A, Loison F, Kangsamaksin T, Jongrungruangchok S, et al
    Terrein inhibits migration of human breast cancer cells via inhibition of the Rho and Rac signaling pathways.
    Oncol Rep. 2018 Jan 4. doi: 10.3892/or.2018.6189.
    PubMed     Text format     Abstract available


    December 2017
  68. WANG Y, Li L, Wang H, Li J, et al
    Silencing TGIF suppresses migration, invasion and metastasis of MDAMB231 human breast cancer cells.
    Oncol Rep. 2017 Dec 4. doi: 10.3892/or.2017.6133.
    PubMed     Text format     Abstract available


    November 2017
  69. LIN SC, Chu PY, Liao WT, Wu MY, et al
    Glycyrrhizic acid induces human MDA-MB-231 breast cancer cell death and autophagy via the ROS-mitochondrial pathway.
    Oncol Rep. 2017 Nov 29. doi: 10.3892/or.2017.6123.
    PubMed     Text format     Abstract available


  70. ANDROUTSOPOULOS VP, Spandidos DA
    Anticancer pyridines induce G2/M arrest and apoptosis via p53 and JNK upregulation in liver and breast cancer cells.
    Oncol Rep. 2017 Nov 28. doi: 10.3892/or.2017.6116.
    PubMed     Text format     Abstract available


  71. SUI Y, Zhang X, Yang H, Wei W, et al
    MicroRNA-133a acts as a tumour suppressor in breast cancer through targeting LASP1.
    Oncol Rep. 2017 Nov 27. doi: 10.3892/or.2017.6114.
    PubMed     Text format     Abstract available


  72. QIU N, He Y, Zhang S, Hu X, et al
    Cullin 7 is a predictor of poor prognosis in breast cancer patients and is involved in the proliferation and invasion of breast cancer cells by regulating the cell cycle and microtubule stability.
    Oncol Rep. 2017 Nov 21. doi: 10.3892/or.2017.6106.
    PubMed     Text format     Abstract available


  73. AOTO K, Mimura K, Okayama H, Saito M, et al
    Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma.
    Oncol Rep. 2017 Nov 14. doi: 10.3892/or.2017.6097.
    PubMed     Text format     Abstract available


  74. ZHANG W, Pan Y, Gou P, Zhou C, et al
    Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model.
    Oncol Rep. 2017 Nov 13. doi: 10.3892/or.2017.6094.
    PubMed     Text format     Abstract available


  75. QIU Y, Liu Y, Li WH, Zhang HQ, et al
    P2Y2 receptor promotes the migration and invasion of breast cancer cells via EMT-related genes Snail and E-cadherin.
    Oncol Rep. 2017 Nov 7. doi: 10.3892/or.2017.6081.
    PubMed     Text format     Abstract available


  76. GONZALEZ-GONZALEZ A, Gonzalez A, Alonso-Gonzalez C, Menendez-Menendez J, et al
    Complementary actions of melatonin on angiogenic factors, the angiopoietin/Tie2 axis and VEGF, in cocultures of human endothelial and breast cancer cells.
    Oncol Rep. 2017 Nov 2. doi: 10.3892/or.2017.6070.
    PubMed     Text format     Abstract available


  77. REN P, Ren X, Cheng L, Xu L, et al
    Frankincense, pine needle and geranium essential oils suppress tumor progression through the regulation of the AMPK/mTOR pathway in breast cancer.
    Oncol Rep. 2017 Nov 1. doi: 10.3892/or.2017.6067.
    PubMed     Text format     Abstract available


    October 2017
  78. JIANG Y, Ji F, Liu Y, He M, et al
    Cisplatin-induced autophagy protects breast cancer cells from apoptosis by regulating yes-associated protein.
    Oncol Rep. 2017 Oct 16. doi: 10.3892/or.2017.6035.
    PubMed     Text format     Abstract available


  79. HOU W, Zhang H, Bai X, Liu X, et al
    Suppressive role of miR-592 in breast cancer by repressing TGF-beta2.
    Oncol Rep. 2017 Oct 12. doi: 10.3892/or.2017.6029.
    PubMed     Text format     Abstract available


  80. HE DX, Wu XL, Lu CX, Gu XT, et al
    Genome-wide analysis of the three-way interplay among gene expression, estrogen receptor expression and chemotherapeutic sensitivity in breast cancer.
    Oncol Rep. 2017 Oct 12. doi: 10.3892/or.2017.6033.
    PubMed     Text format     Abstract available


  81. YANG L, Song Z, Wang X, Yang W, et al
    Huaier extract enhances the treatment efficacy of paclitaxel in breast cancer cells via the NF-kappaB/IkappaBalpha pathway.
    Oncol Rep. 2017 Oct 12. doi: 10.3892/or.2017.6024.
    PubMed     Text format     Abstract available


  82. HAN Y, Zhang L, Wang W, Li J, et al
    Livin promotes the progression and metastasis of breast cancer through the regulation of epithelialmesenchymal transition via the p38/GSK3beta pathway.
    Oncol Rep. 2017 Oct 10. doi: 10.3892/or.2017.6017.
    PubMed     Text format     Abstract available


    September 2017
  83. ZHOU T, Zhang A, Kuang G, Gong X, et al
    Baicalin inhibits the metastasis of highly aggressive breast cancer cells by reversing epithelial-to-mesenchymal transition by targeting beta-catenin signaling.
    Oncol Rep. 2017 Sep 28. doi: 10.3892/or.2017.6011.
    PubMed     Text format     Abstract available


  84. ONO H, Iizumi Y, Goi W, Sowa Y, et al
    Ribosomal protein S3 regulates XIAP expression independently of the NF-kappaB pathway in breast cancer cells.
    Oncol Rep. 2017 Sep 27. doi: 10.3892/or.2017.6008.
    PubMed     Text format     Abstract available


  85. AN J, Wang L, Zhao Y, Hao Q, et al
    Effects of FSTL1 on cell proliferation in breast cancer cell line MDAMB231 and its brain metastatic variant MDAMB231BR.
    Oncol Rep. 2017 Sep 26. doi: 10.3892/or.2017.6004.
    PubMed     Text format     Abstract available


  86. ZHANG Y, Wang DL, Yan HY, Liao JY, et al
    Genome-wide study of ER-regulated lncRNAs shows AP000439.3 may function as a key regulator of cell cycle in breast cancer.
    Oncol Rep. 2017 Sep 20. doi: 10.3892/or.2017.5975.
    PubMed     Text format     Abstract available


  87. TANG CP, Zhou HJ, Qin J, Luo Y, et al
    MicroRNA-520c-3p negatively regulates EMT by targeting IL-8 to suppress the invasion and migration of breast cancer.
    Oncol Rep. 2017 Sep 19. doi: 10.3892/or.2017.5968.
    PubMed     Text format     Abstract available


  88. ZHAO Y, Ge CC, Wang J, Wu XX, et al
    MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing beta-catenin nuclear accumulation.
    Oncol Rep. 2017 Sep 13. doi: 10.3892/or.2017.5955.
    PubMed     Text format     Abstract available


    June 2017
  89. XU W, Wu B, Fu L, Chen J, et al
    Comparison of three different methods for the detection of circulating tumor cells in mice with lung metastasis.
    Oncol Rep. 2017;37:3219-3226.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: